Are you or your loved ones suffering from metastatic neuroendocrine tumor?

You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Are you or your loved ones suffering from metastatic neuroendocrine tumor? You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Neuroendocrine Tumors in Cleveland OH
NCT03034200 | Phase 2 | Interventional
Peter Anderson
Sponsored by
Peter Anderson

Are you or your loved ones suffering from metastatic neuroendocrine tumor?

You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Are you or your loved ones suffering from metastatic neuroendocrine tumor? You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Recruiting

Male & Female

18 +

years old

This study is looking to recruit 24 Participants

The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in neuroendocrine cancers including PC-PG. ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase 1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.

Interested in participating?
Selected location

Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center

Cleveland, OH, USA 44195

Peter M Anderson, MD, PhD 216-445-4007
andersp@ccf.org


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.